497 related articles for article (PubMed ID: 15476662)
1. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
2. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
4. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline--novel cytotoxic DNA topoisomerase II inhibitors.
Godlewska J; Luniewski W; Zagrodzki B; Kaczmarek L; Bielawska-Pohl A; Dus D; Wietrzyk J; Opolski A; Siwko M; Jaromin A; Jakubiak A; Kozubek A; Peczyñska-Czoch W
Anticancer Res; 2005; 25(4):2857-68. PubMed ID: 16080538
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
7. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
9. Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents.
Hu C; Xu D; Du W; Qian S; Wang L; Lou J; He Q; Yang B; Hu Y
Mol Biosyst; 2010 Feb; 6(2):410-20. PubMed ID: 20094661
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
11. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
12. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
13. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
14. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
Ryckebusch A; Garcin D; Lansiaux A; Goossens JF; Baldeyrou B; Houssin R; Bailly C; Hénichart JP
J Med Chem; 2008 Jun; 51(12):3617-29. PubMed ID: 18507368
[TBL] [Abstract][Full Text] [Related]
18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
[TBL] [Abstract][Full Text] [Related]
20. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]